Phase Ib study of the mitochondrial inhibitor ME-344 plus topotecan in patients with previously treated, locally advanced or metastatic small cell lung, ovarian and cervical cancers

Combine and conquer: challenges for targeted therapy combinations in early phase trials

(2016) Juanita S. Lopez et al.   Nature Reviews Clinical Oncology

A novel isoflavone, ME-344, targets the cytoskeleton in acute myeloid leukemia

(2016) Danny V. Jeyaraju et al.   Oncotarget

Targeting Tumor Mitochondrial Metabolism Overcomes Resistance to Antiangiogenics

(2016) Paloma Navarro et al.   Cell Reports

Systematic Review of topotecan (Hycamtin) in relapsed small cell lung cancer

(2016) Rob Riemsma et al.   BMC CANCER

Systemic therapy for recurrent, persistent, or metastatic cervical cancer: a clinical practice guideline

(2015) H. Hirte et al.   Current Oncology

Phase 1, open-label, dose escalation, safety, and pharmacokinetics study of ME-344 as a single agent in patients with refractory solid tumors

(2014) Johanna C. Bendell et al.   CANCER

Weekly Topotecan for Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma

(2013) Tamar Safra et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Targeting the Mitochondria Activates Two Independent Cell Death Pathways in Ovarian Cancer Stem Cells

(2011) A. B. Alvero et al.   MOLECULAR CANCER THERAPEUTICS

Therapeutic Targeting of Mitochondrial Superoxide in Hypertension

(2010) Anna E. Dikalova et al.   CIRCULATION RESEARCH

Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: A Randomized Multicenter Phase II Trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group

(2010) Jalid Sehouli et al.   JOURNAL OF CLINICAL ONCOLOGY

NV-128, a novel isoflavone derivative, induces caspase-independent cell death through the Akt/mammalian target of rapamycin pathway

(2009) Ayesha B. Alvero et al.   CANCER